Levorrac M Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, formulated to provide effective relief from allergic conditions. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, nasal congestion, rhinorrhea, and itching associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks the action of cysteinyl leukotrienes, which play a key role in the pathophysiology of asthma and allergic rhinitis by causing bronchoconstriction, mucus secretion, and inflammation. The synergistic action of these two agents offers comprehensive management of allergic respiratory disorders, improving patient outcomes by addressing both histamine-mediated and leukotriene-mediated pathways. Levorrac M is indicated for the treatment of seasonal and perennial allergic rhinitis, chronic idiopathic urticaria, and as an adjunct therapy in asthma management to reduce bronchospasm and inflammation. The tablet is generally well tolerated; common adverse effects may include headache, dry mouth, and gastrointestinal discomfort. Caution is advised in patients with hepatic or renal impairment. Levorrac M should be used under medical supervision, with dosage adjustments as necessary based on clinical response and patient condition.